Novel molecules that interact with microtubules and have functional activity similar to Taxol™

Drug Discovery Today

Volumn 6, Issue 22, 2001, Pages 1153-1164

  He, Lifeng ^a   Orr, George A ^a   Horwitz, Susan Band ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

BINDING SITE; DRUG DEVELOPMENT; DRUG TARGETING; ESCHERICHIA COLI; GENE EXPRESSION; NONHUMAN; OPERON; REVIEW;

EID: 0035889710     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)02038-4     Document Type: Review

References (84)

1. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
2. The taxoids: paclitaxel and docetaxel
3. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
4. Promotion of microtubule assembly in vitro by taxol
5. Taxol binds to polymerized tubulin in vitro
6. Low resolution structure of microtubules in solution. Synchrotron X-ray scattering and electron microscopy of taxol-induced microtubules assembled from purified tubulin in comparison with glycerol and MAP-induced microtubules
7. Taxol stabilizes microtubules in mouse fibroblast cells
8. Substoichiometric binding of taxol suppresses microtubule dynamics
9. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
10. Direct photoaffinity labeling of tubulin with taxol
11. 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of β-tubulin
12. Characterization of the taxol binding site on the microtubule. 2-(m-azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of β-tubulin
13. Characterization of the Taxol binding site on the microtubule. Identification of Arg282 in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol
14. Structure of the α,β-tubulin dimer by electron crystallography
15. High-resolution model of the microtubule
16. The binding conformation of Taxol in β-tubulin: a model based on electron crystallographic density
17. How Taxol stabilises microtubule structure
18. Crystal structure of the bacterial cell-division protein FtsZ
19. Tubulin and FtsZ form a distinct family of GTPases
20. Role of nucleotide hydrolysis in microtubule assembly
21. Guanosinetriphosphatase activity of tubulin associated with microtubule assembly
22. Stability of tubulin polymers formed with dideoxyguanosine nucleotides in the presence and absence of microtubule-associated proteins
23. Interactions of tubulin with guanine nucleotides that have paclitaxel-like effects on tubulin assembly: 2′,3′-dideoxyguanosine 5′-[α,β-methylene]triphosphate, guanosine 5′-[α,β-methylene]triphosphate, and 2′,3′-dideoxyguanosine 5′-triphosphate
24. Microtubule structure at improved resolution
25. P-glycoprotein and multidrug resistance
26. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
27. Taxol: mechanisms of action and resistance
28. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells
29. Synthesis and structure-activity relationships of new second-generation taxoids
30. Synthesis of highly potent second-generation taxoids through effective kinetic resolution coupling of racemic (-lactams with baccatins
31. Anti-proliferative activity of a new class of taxanes (14-beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells
32. IDN5109, a taxane with oral bioavailability and potent antitumor activity
33. Oral efficacy and bioavailability of a novel taxane
34. Effects of orally active taxanes on p-glycoprotein modulation and colon and breast carcinoma drug resistance
35. Tumor targeting by conjugation of DHA to paclitaxel
36. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physicochemical and biological properties
37. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
38. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines
39. Total synthesis of (-)-epothilone A
40. Synthesis of epothilones A and B in solid and solution phase
41. Cloning and heterologous expression of the epothilone gene cluster
42. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90
43. Structure-activity relationships of the epothilones and the first in vivo comparison with paclitaxel
44. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice
45. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
46. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
47. Properties of p19, a novel cAMP-dependent protein kinase substrate protein purified from bovine brain
48. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules
49. The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation
50. Discodermolide - a new, marine-derived immunosuppressive compound. I. In vitro studies
51. Discodermolide - a new, marine-derived immunosuppressive compound. II. In vivo studies
52. Immunosuppression by discodermolide
53. Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest
54. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
55. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) totubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells
56. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies
57. Distinct binding and cellular properties of synthetic (+)- and (-)-discodermolides
58. Acetylated analogues of the microtubule-stabilizing agent discodermolide: preparation and biological activity
59. Structure-activity relationship studies of discodermolide and its semisynthetic acetylated analogs on microtubule function and cytotoxicity
60. Gram-scale synthesis of (+)-discodermolide
61. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules
62. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol)
63. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site
64. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines
65. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents
66. A model for the Taxol (paclitaxel)/epothilone pharmacophore
67. A common pharmacophore for cytotoxic natural products that stabilize microtubules
68. A unified and quantitative receptor model for the microtubule binding of paclitaxel and epothilone
69. A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain
70. Solution structure of (+)-discodermolide
71. The conformations of discodermolide in DMSO
72. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans
73. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein
74. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
75. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations
76. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity
77. Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro